@KUMedicine alum | IM via @CUInternalMed | Current PGY4 @UtahHemeOnc @HuntsmanCancer Fellow | interested in lymphoma and QOL
Joined February 2022
- Tweets 62
- Following 360
- Followers 159
- Likes 783
18 Photos and videos
Pinned Tweet
18 Dec 2024
Oral agents have changed the CLL treatment landscape. But how does their cost affect patients? Here's a review of our #ASH24 abstract on the relationship between financial toxicity, medication adherence, and health-related QOL in CLL pts on 1L oral therapy #lymsm š§µ/1
1
3
15
2,922
Jessica Allen retweeted
Jun 5
š¢ @ASCO: Improved real-world efficacy was shown for frontline zanubrutinib monotherapy compared with other BTK inhibitors in older patients with CLL.
Full details š: onclive.com/view/first-line-ā¦
#leusm #oncology #ASCO26
1
6
519
Jessica Allen retweeted
Jun 2
This is the silent part that people wouldn't know.
Behind closed doors inside a medical conference, a large group of clinicians and researchers giving a standing ovation to another group of clinicians and researchers who found a way to increase survival in patients suffering from one of the, if not the, worst cancer in humans.
Metastatic pancreatic cancer.
They'll do this and then be on their way to see their patients the next day as if nothing happened.
And then work on something new to better what they did in this room.
That is how medical science works.
Value it and value its practitioners.
May 31
One of the most amazing things Iāve ever seen: a standing ovation for the full Daraxonrasib results
I feel inspired and energised, to put it mildly ā we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore
40
697
4,769
206,912
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM
#ASCO26 | @ASCO
ALT A two-panel line graph shows overall survival in two populations, comparing darovasertib (blue line) and chemotherapy (gray line) treatments. Panel A depicts the RAS G12 population, while Panel B shows the overall population. Hazard ratios and confidence intervals are detailed in each panel.
ALT This image shows two line graphs titled "Progression-free Survival in the RAS G12 Population" and "Progression-free Survival in the Overall Population." Both graphs compare survival rates over 13 months between two groups: one receiving darovasertib and the other receiving chemotherapy. Accompanying the graphs are tables detailing the number of events and patients at risk for each treatment group.
8
348
1,199
69,313
Jessica Allen retweeted
May 31
One of the most amazing things Iāve ever seen: a standing ovation for the full Daraxonrasib results
I feel inspired and energised, to put it mildly ā we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore
104
1,499
9,558
1,975,022
Jessica Allen retweeted
May 31
The overall survival curves for Daraxonrasib in 2nd line advanced #PancreaticCancer leave no doubt how impactful this advance is for the field & for patients. Congratulations Brian Wolpin, @EileenMOReilly & @md_oberstein et al.
A seminal #ASCO26 plenary!
nejm.org/doi/full/10.1056/NEā¦
2
64
200
14,331
Jessica Allen retweeted
May 31
Donāt typically see these kinds of headlines in #PancreaticCancer but todayās #ASCO26 plenary on @RevMedicines Daraxonrasib brings it.
āLandmarkā pancreatic cancer drug keeps patients alive for twice as long
By @Carolynyjohnson @washingtonpost
washingtonpost.com/health/20ā¦
1
10
31
3,086
May 31
This is truly so exciting. My dad was diagnosed with pancreatic cancer the week before my college graduation, and he was the reason I went into oncology. I am so excited to see this progress for patients like him.
As many other oncologists will also attest, we were taught this was a dead end
It was, dogmatically, never going to work ā kras was too much of a āgreasy ballā to be targeted
And yet here we are, with truly meaningful survival curvesš
Inspiration on multiple levels #ASCO26
5
139
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
52
2,055
5,577
2,470,780
May 30
Honored to present our CUBIC study on real-world outcomes in bispecific antibodies in relapsed/refractory follicular lymphoma. In a cohort of 99 patients, these therapies appear similarly as safe and effective as demonstrated in clinical trial populations. Manuscript coming soon!
1
3
9
1,906
May 30
Biggest thanks to my mentors Dr. Alli Bock and Dr. Sairah Ahmed, my co-author Rahul Shah, and all participating CUBIC institutions. It was also very special to present on a panel led by one of my mentors at Colorado, @mana1981, and to collaborate with another CU mentor @majorajay
2
1
5
227
May 30
My 19 year old self, who very consciously chose to take public speaking as an online course, would not believe her eyes!
3
85
Jessica Allen retweeted
May 28
And, ePRO monitoring has an OS benefit! #ASCO26
- ~40k pts across 6 health systems using EHR-integrated eSyM system
eSyM users had better OS than non-users:
- Chemo: HR 0.63, absolute 1-yr OS benefit 10.2%
- Surg onc: HR 0.58, absolute 1-yr OS benefit 2.8%
Many of our anti-cancer therapies don't even have this level of evidence! #onctwitter
We are one of the first participating sites in the OncoPRO Initiative, now presented at #ASCO26.
We implemented ePRO monitoring @CUCancerCenter (spearheaded by Dr. @majorajay) as part of routine cancer care to better support patients during treatment.
asco.org/abstracts-presentatā¦
1
3
7
1,331
Jessica Allen retweeted
May 28
RW bispecific outcomes R/R FL (CUBIC Consortium) #ASCO26
- 99 pts, median 3 prior lines, 15% prior CAR
- ORR 87%, CRR 72%
- 1-yr PFS 72%, 18-mo OS 92%
- PFS not affected by BsAb type or prior CAR
- outcomes similar for older/very elderly pts
- CRS 34% (mostly G1, no G3 ), ICANS 3% (all G1)
Encouraging data for BsAb across diverse/heavily pretreated FL, including older adults. #lymsm #geriheme
asco.org/abstracts-presentatā¦
9
21
1,080
Jessica Allen retweeted
Congratulations to former @CUMedicalSchool resident Dr. @JessicaAllenMD on her #ASCO26 oral presentation on real-world outcomes of bispecifics in R/R FL, from the CUBIC Consortium. Multiple @CUHematology faculty contributed. #lymsm
asco.org/abstracts-presentatā¦
3
3
601
May 27
Congratulations to an incredible physician and person!
May 26
to Dr. Gli Fortuna for being accepted into the prestigious ASH CRTI! @ash_hematology @UofUInternalMed @UofUHealth
3
547
Jessica Allen retweeted
May 23
Our study on patient-reported time toxicity of BsAb in R/R FL & DLBCL:
- 120 pts actively receiving BsAb tx
- fixed-duration BsAb (glofi, mosun) = less healthcare contact days & ~50% less time burden (vs epco)
- no difference in infusion time between IV and SQ
Time-limited & less frequent BsAb dosing translates into meaningful reductions in time toxicity, both in the clinic and at home. #lymsm
academic.oup.com/oncolo/advaā¦
4
12
40
6,047
Jessica Allen retweeted
Itās strange that we ask trainees to read clinical trials but never really teach them how to read clinical trials.
Iād request all training program directors and mentors to please share this article to their trainees and fellows- ascopubs.org/doi/10.1200/OP-ā¦
Grateful to @JCOOP_ASCO for making this free.
A MUST-READ!
This is probably one of my most important papers where I try to teach how to fish rather than offer fish.
How I Read a Clinical Trial Report?
BGās primer for Busy Clinicians.
Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful.
ascopubs.org/doi/10.1200/OP-ā¦
9
126
528
113,125
Jessica Allen retweeted
Apr 21
What are plenary sessions for ASCO 2026 ?
Titles are just out
Watch out šš @ASCO #asco2026 @Alfdoc2 @APassaroMD @dr_yakupergun @OncBrothers @OncoAlert @MedwatchKate @FordePatrick @DrJNaidoo @MyriamChalabi @DrChoueiri
2
59
175
22,031
Jessica Allen retweeted
Conquer Cancer is thrilled to announce our support of 141 recipients of 2026 ASCO Annual Meeting Merit Awards and 5 Special Merit Awards. These awards support students and trainees with outstanding research for presentation at the 2026 ASCO Meeting. Special Merit Awards are presented to top-ranking abstracts. See the list of recipients: bit.ly/4sNlFfa
@ASCO #ASCO26 #ResearchConquersCancer #ConquerCancer
1
17
66
22,780
Jessica Allen retweeted
27 Oct 2025
šØJust out @CCR_AACR šØ
V proud of our manuscript on polatuzumab efficacy by cell of origin in DLBCL
We show COO by Hans predicts pola sensitivity in 740 pts
Pts w R/R non-GCB DLBCL have higher ORR, CRR & PFS
Massive thanks @dgermain21 & collabs!
aacrjournals.org/clincancerrā¦
7
27
86
12,881